Lupin Limited Q4 FY26 Earnings Call Transcript Released
Lupin Limited released its Q4 FY26 earnings call transcript on May 8, 2026. The company reported record revenues and profitability for FY26. Q4 FY26 revenue grew 32% YoY to ₹7,475 crore, with EBITDA up 68% YoY to ₹2,171 crore. Full-year revenue was ₹27,958 crore (up 23% YoY). The US business grew 40% YoY to USD 1.3 billion. The company expects high single-digit revenue growth and ~25% EBITDA margins for FY27.
This announcement provides detailed financial results, strategic updates, and future guidance from a major pharmaceutical company, which is highly material for investors and the market.
The announcement is a transcript of an earnings call where the company reported record revenues and profitability, strong growth across key geographies, and provided a positive outlook for the next fiscal year. Management highlighted significant achievements and future growth drivers.
Lupin Limited has released the transcript of its Q4 FY2026 Earnings Conference Call, which was held on May 08, 2026.
The call featured key management personnel including Ms. Vinita Gupta (CEO), Mr. Nilesh Gupta (Managing Director), Mr. Ramesh Swaminathan (Executive Director, Global CFO), and Mr. Ravi Agrawal (M&A and Investor Relations).
During the call, the management highlighted a strong performance for FY26, with revenues and profitability reaching record levels. The US business showed significant growth, achieving sales of USD 1.3 billion for the full year, a nearly 40% year-over-year increase, driven by new products and complex injectables. The India business also demonstrated robust growth of 11.5% year-over-year in the quarter, with the core prescription business growing by 14.5%.
Other Developed Markets (Europe, Canada, Australia) contributed 12% to total sales and grew by 13.3% in FY26. Emerging Markets reported an impressive 49% year-over-year growth in the quarter, led by Brazil, South Africa, and the Philippines. The company also provided an outlook for FY27, expecting high single-digit top-line growth with margins around 25% despite potential headwinds.
Financially, for Q4 FY26, total revenue from operations grew 32% year-over-year to ₹7,475 crores, and EBITDA grew 68% year-over-year to ₹2,171 crores. For the full year FY26, total revenues were ₹27,958 crores (up 23% YoY), and EBITDA (excluding forex and other income) was ₹8,160 crores (up 55% YoY), with EBITDA margins at 29.7%.
The company also discussed its R&D spend, which was 8% of sales in Q4 FY26 and 7.5% for FY26, with a continued focus on complex and specialty platforms. Compliance efforts were also mentioned, including receiving the EIR for Goa and VAI status from the USFDA. Discussions also covered strategic capital allocation, potential acquisitions, and future product launches in various segments, including biosimilars and specialty products.
What to do with a filing like this
Lupin Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lupin Limited. Read the original for the full detail.